Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Bladder cancer: Dose-dense MVAC yields improved response, survival
Peyton CC et al. JAMA Oncology. 2018 Aug 30. doi: 10.1001/jamaoncol.2018.3542.
Key clinical point: Neoadjuvant chemotherapy with dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (ddMVAC) is associated with improved response and survival rates, compared with gemcitabine-based regimens.
Major finding: 2-year survival probability with ddMVAC was 73.3% vs. 62% for gemcitabine-cisplatin and 34.8% for gemcitabine-carboplatin (P = .002).
Study details: Retrospective cross-sectional analysis of data on 1,113 patients with muscle-invasive bladder cancer.
Disclosures: The study was supported in part by a National Cancer Institute grant to the H. Lee Moffitt Cancer Center. The authors reported having no conflicts of interest.
Peyton CC et al. JAMA Oncology. 2018 Aug 30. doi: 10.1001/jamaoncol.2018.3542.